Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Bailliere'S Clinical Haematology
|
December 1, 1995
Immunophenotype and DNA cell content in multiple myeloma
J F San Miguel, R Garcia-Sanz, M Gonzalez, et al.
Leukemia Research
|
June 1, 1995
In vitro autonomous proliferation in ANLL: clinical and biological significance
J Almeida, C del Cañizo, A Orfao, et al.
Leukemia
|
March 13, 2001
Immunoglobulin lambda isotype gene rearrangements in B cell malignancies
T Tümkaya, M van der Burg, R Garcia Sanz, et al.
Annals of Hematology
|
March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
A Palumbo, F Davies, M Kropff, et al.
Thrombosis Research
|
September 29, 2006
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism
J R Gonzalez-Porras, F Martin-Herrero, R Garcia-Sanz, et al.
Annals of Hematology
|
January 5, 2002
Association of CD4+/CD56+/CD57+/CD8+(dim) large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosis
M Lima, C Gonçalves, L Marques, et al.
Leukemia
|
May 24, 2003
Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities
D Primo, M D Tabernero, A Rasillo, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
M V Mateos, R Garcia-Sanz, R López-Pérez, et al.
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R Garcia-Sanz, A Sureda, F de la Cruz, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Bailliere'S Clinical Haematology
|
December 1, 1995
Immunophenotype and DNA cell content in multiple myeloma
J F San Miguel, R Garcia-Sanz, M Gonzalez, et al.
Leukemia Research
|
June 1, 1995
In vitro autonomous proliferation in ANLL: clinical and biological significance
J Almeida, C del Cañizo, A Orfao, et al.
Leukemia
|
March 13, 2001
Immunoglobulin lambda isotype gene rearrangements in B cell malignancies
T Tümkaya, M van der Burg, R Garcia Sanz, et al.
Annals of Hematology
|
March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
A Palumbo, F Davies, M Kropff, et al.
Thrombosis Research
|
September 29, 2006
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism
J R Gonzalez-Porras, F Martin-Herrero, R Garcia-Sanz, et al.
Annals of Hematology
|
January 5, 2002
Association of CD4+/CD56+/CD57+/CD8+(dim) large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosis
M Lima, C Gonçalves, L Marques, et al.
Leukemia
|
May 24, 2003
Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities
D Primo, M D Tabernero, A Rasillo, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
M V Mateos, R Garcia-Sanz, R López-Pérez, et al.
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
R Garcia-Sanz, A Sureda, F de la Cruz, et al.
Page
of 2